{"id":"NCT00688376","sponsor":"Eisai Inc.","briefTitle":"Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment","officialTitle":"Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-07-02","primaryCompletion":"2009-05-26","completion":"2009-05-26","firstPosted":"2008-06-02","resultsPosted":"2020-03-27","lastUpdate":"2022-01-05"},"enrollment":72,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Attention Impairment"],"interventions":[{"type":"DRUG","name":"Donepezil hydrochloride","otherNames":["Aricept"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy, safety and tolerability of donepezil in children with persistent attention impairment that is present at least 12 months after the completion of cancer treatment.","primaryOutcome":{"measure":"Change From Baseline in the Test of Variables in Attention-Continuous Performance Test (TOVA-CPT) \"D-prime\" Standard Score (SS) at Week 12","timeFrame":"Baseline and Week 12","effectByArm":[{"arm":"Donepezil","deltaMin":5.2,"sd":8.77},{"arm":"Placebo","deltaMin":4.5,"sd":7.39}],"pValues":[{"comp":"OG000 vs OG001","p":"0.694"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":31,"countries":["United States","Argentina","Australia","Canada","Chile","France","Germany","Netherlands","Spain","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":40},"commonTop":["Headache","Nausea","Abdominal pain","Nasopharyngitis","Vomiting"]}}